BackAdaptive Biotechnologies Overview
Adaptive Biotechnologies Corp

Adaptive Biotechnologies Target Price

Where could ADPT trade next? Consensus target price: $24.

Get informed when a big investor buys or sells

+ Follow

Share Price

$24.28

Average Target Price

$23.901.6% downside

5 analysts in the last 4 months

High: $27.5 | Low: $20

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-04Piper Sandler$27.513.3% upsideOpen
2026-07-30Guggenheim$253% upsideOpen
2026-07-30BTIGMark Massaro$253% upsideOpen
2026-07-09Morgan Stanley$2017.6% downsideOpen
2026-06-29Guggenheim$229.4% downsideOpen
2026-02-06BTIG$229.4% downsideOpen
2026-02-06Piper SandlerSebastian Sandler$2113.5% downsideOpen
2026-01-26Guggenheim$2113.5% downsideOpen
2025-12-01Morgan StanleyKallum Titchmarsh$2113.5% downsideOpen
2025-10-15Piper Sandler$2017.6% downsideOpen
2025-09-30Guggenheim$2017.6% downsideOpen
2024-04-04BTIGMark Massaro$579.4% downsideOpen
2022-12-21Piper SandlerDavid Westenberg$1442.3% downsideOpen
2022-08-17Piper SandlerDavid Westenberg$1250.6% downsideOpen
2022-06-13Piper SandlerDavid Westenberg$7.569.1% downsideOpen
2022-05-06Morgan Stanley$1825.9% downsideOpen

Adaptive Biotechnologies (ADPT) FAQ

Adaptive Biotechnologies (ADPT) currently reports a target price of $24. Use the charts on this page to explore Adaptive Biotechnologies's target price history and peer comparisons.

Analysts' average 12-month price target for Adaptive Biotechnologies is $24, about 1.6% downside from the current share price of $24.28. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $24, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Adaptive Biotechnologies, and consider following ADPT for alerts when major investors trade the stock.

Adaptive Biotechnologies is classified in the Healthcare sector. On target price, it currently shows $24. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADPT with unrelated industries.